SciNeuro
SciNeuro Raises $53 million in Series B
SciNeuro Raises $53 million in Series B
SciNeuro has successfully raised $53 million in a Series B at a Undisclosed led by Chinese.
Company Overview
SciNeuro is a Biotechnology company headquartered in Shanghai China, founded in 2016 with 100+ employees.
SciNeuro secured funding for its pipeline of neurodegenerative disease therapies. The company focuses on developing treatments for Alzheimers Parkinsons and other neurological conditions using novel drug candidates.
Fundraising Details
- Amount Raised: $53 million
- Round Type: Series B
- Valuation: Undisclosed
- Date: 2025-11-18
- Investors: Chinese and international biotech investors
About SciNeuro
SciNeuro secured funding for its pipeline of neurodegenerative disease therapies. The company focuses on developing treatments for Alzheimers Parkinsons and other neurological conditions using novel drug candidates. The company is positioned in the Biotechnology sector, serving a growing market with innovative solutions.
Key Information
- Headquarters: Shanghai China
- Founded: 2016
- Team Size: 100+
- Industry: Biotechnology
What This Means
This funding round demonstrates strong investor confidence in SciNeuro's vision and execution. The capital will likely be used to:
- Scale Operations: Expand the team and operational capacity
- Product Development: Enhance existing products and develop new features
- Market Expansion: Enter new markets and strengthen presence in existing ones
- Technology Investment: Invest in infrastructure and technology capabilities
Industry Context
The Biotechnology sector continues to attract significant investment as companies innovate to meet evolving market demands. SciNeuro's successful fundraising reflects the strong fundamentals and growth potential in this space.
Valuation Milestone
Reaching Undisclosed marks an important milestone for SciNeuro, positioning the company among notable players in the Biotechnology industry.
Looking Ahead
With this new capital, SciNeuro is well-positioned to execute on its growth strategy and continue building innovative solutions in the Biotechnology space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.
This fundraising news was reported on 2025-11-18. For more information about SciNeuro, visit their headquarters at Shanghai China.
Company Info
Investors (2)
Share
Related Reports
Tenstorrent Raises $693M in Series D | AI Hardware Achieves $2.7B Valuation
AI hardware company Tenstorrent secures $693 million Series D funding led by Samsung Securities, reaching $2.7 billion valuation.
Perplexity Raises $500M Series D | AI Search Engine Valued at $9B
AI-powered search engine Perplexity secures $500 million in Series D funding led by SoftBank, achieving $9 billion valuation.
One Raises $300M | Walmart-Backed Digital Bank Expands Services
Digital banking platform One secures $300 million led by Walmart to expand its financial wellness offerings.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free